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Abstract
gd T lymphocytes are a numerically small subset of T cells with potent cytotoxic activity against a
variety of tumor cells. Human gd T cells expressing the Vg9Vd2 T cell antigen receptor recognize
endogenous pyrophosphate molecules that are overproduced in transformed cells. Moreover, the
intracellular accumulation of such pyrophosphates is strongly enhanced by aminobisphosphonates
used in the treatment of osteoporosis and bone metastasis in certain cancer patients. A new concept
of cancer immunotherapy is based on the endogenous activation of gd T cells with aminobispho-
sphonates plus low-dose interleukin-2.
Introduction and context
Approximately 1-5% of peripheral blood T cells express
the gd T-cell receptor instead of the conventional ab
T-cell receptor [1]. The ab versus gd T-cell lineage
commitment during intrathymic T-cell development
seems to be controlled by the signal strength provided
to the gd T-cell receptor [2]. In healthy donors, most
blood gd T cells carry a specific T-cell receptor composed
of Vg9a n dV d2 elements. In addition to effector
functions shared with ab T cells, the Vg9Vd2 T cells can
acquire professional antigen-presenting capacity charac-
teristic of dendritic cells [3]. In contrast to ab T cells,
Vg9Vd2 T cells do not see processed antigenic peptides
presented by major histocompatibility complex mole-
cules, but rather recognize small phosphorylated non-
peptide molecules (‘phosphoantigens’) produced by
many microorganisms but also by transformed eukar-
yotic cells [4,5]. While microbial phosphoantigens are
active at pico- to nanomolar concentrations, micromolar
concentrations of the eukaryotic phosphoantigen iso-
pentenyl pyrophosphate (IPP) are required for gd T-cell
activation. Such high concentrations are not achieved in
the mevalonate pathway of isoprenoid synthesis used in
non-transformed cells. Interestingly, human Vg9Vd2
T cells can kill a broad variety of epithelial tumor and
leukemia/lymphoma cells [6,7]. The sensitivity of tumor
cells to gd T-cell-mediated killing is increased upon
treatment of tumor cells with aminobisphosphonates
(N-BPs), drugs that are used in clinical practice for the
treatment of osteoporosis and bone metastasis in cancer
patients [8]. N-BPs inhibit the IPP-processing enzyme
farnesyl diphosphate synthase (FPPS), thereby leading
to an accumulation of IPP, which is then sensed by the
gd T cells [9]. gd T cells are poor producers of interleukin-
2 (IL-2), which is required for expansion of gd T cells.
Therefore, attempts to activate tumor-reactive gd T cells
endogenously by treating patients with N-BPs must take
into consideration an appropriate supply of IL-2.
Alternative strategies consider the adoptive transfer of
in vitro expanded tumor-reactive gd T cells [10-14].
Recent advances
The critical role of FPPS in the control of intracellular IPP
levels, and thus of the sensitivity of tumor cells toward gd
T-cell killing, has been recently demonstrated using short
hairpin RNA-mediated knock-down of FPPS [15].Knock-
down of FPPS caused tumor cells, which otherwise were
not recognized by gd T cells, to be susceptible to gd T-cell
killing [15]. Therefore, Vg9Vd2 T cells recognize and kill
tumor cells on the basis of the unbalanced isoprenoid
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stable in non-malignant cells.
The discovery that N-BPs activate gd T cells by inhibiting
FPPS, thereby leading to accumulation of IPP, has paved
the way for proof-of-principle studies to activate gd T cells
inpatientswithadvancedcancer.InaphaseIclinicaltrial,
Dieli and colleagues [16] treated patients with hormone-
refractory prostate cancer with a standard application
of the N-BP zoledronate (4 mg intravenous infusion
every21days)eitherwithorwithoutadditionallow-dose
(6 × 10
5 IU) subcutaneous application of IL-2. Various
parameters, including subset analysis of gd T cells, and
serum levels of prostate-specific antigen and cytokines,
were monitored over time. Although the two cohorts
comprised only a few patients, statistically significant
effects of zoledronate plus IL-2 on the mobilization and
effector cell maturation of gd T cells were recorded. Very
importantly, the two cohorts showed distinct clinical
outcomes, with clinical responses seen in six of nine
patients treated with zoledronate plus IL-2 but only in
one of nine patients treated with zoledronate alone.
Interestingly, a correlation between favorable outcome at
12 months and gd T-cell numbers or functional status (or
both) was observed [16]. Similarly, Wilhelm and
colleagues had previously shown that the combined
application of N-BP plus low-dose IL-2 can induce
objective tumor responses in patients with lymphoid
malignancies [17]. Together, these studies support the
view that application of N-BPs plus IL-2 is safe, induces
in vivo activation/maturation of gd T cells, and may have
beneficial effects in advanced cancer (Figure 1a).
Figure 1. Approaches to immunotherapy with gd T cells
(a) N-BPs inhibit farnesyl diphosphate synthase (FPPS), thus preventing processing of isopentenyl pyrophosphate (IPP) to farnesyl diphosphate (FPP). This
leads to accumulation of IPP which then activates Vg9Vd2 T cells. Vg9Vd2 T cells require exogenous interleukin (IL)-2 for cellular expansion. The combined
application of N-BP plus IL-2 leads to in vivo activation of gd T cells. (b) Alternatively, gd T cells can be activated in vitro with N-BP or synthetic
phosphoantigens in the presence of antigen-presenting cells (APC) and can be subsequently expanded to large cell numbers by an exogenous supply of IL-2 for
subsequent adoptive transfer into cancer patients. The cell preparation can be performed under GMP (Good Manufacturing Practice) conditions.
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of lung and bone metastases was observed in a patient
with advanced stage melanoma upon systemic treatment
with zoledronate and localized radiotherapy. Although
gd T-cell subsets were analyzed, it is difficult to ascertain
a substantial role of gd T-cell activation in the resolution
of metastases in this single case, particularly since IL-2
was omitted in the treatment of this patient [18].
In addition to their gd T-cell activating properties, N-BPs
also exhibit direct anti-tumor activities by both inhibit-
ing proliferation and inducing apoptosis in tumor cells
[19]. While zoledronate seems to be the most potent
gd T-cell-activating substance among the N-BPs licensed
for clinical application [9], derivatives of zoledronate
with further improved gd T-cell-stimulating capacity and
enhanced direct anti-tumor activity are under develop-
ment [20]. Such modified N-BPs might also exert
improved in vivo activation of gd T cells when given to
patients together with IL-2.
An alternative and not mutually exclusive gd T-cell-based
immunotherapeutic strategy is the adoptive transfer of
in vitro expanded Vg9Vd2 T cells from tumor patients
(Figure 1b). Recently, efficient protocols for the large-
scale in vitro expansion of Vg9Vd2 T cells based on
stimulation with synthetic phosphoantigens [11,13,14]
or zoledronate [21] have been established. First results
indicate that the repetitive adoptive transfer of in vitro
expanded gd T cells is well tolerated and may induce anti-
tumor responses in patients with solid tumors, including
renal cell carcinoma [13,14] and myeloma [12].
Implications for clinical practice
The protocol developed by Dieli et al. [16] for the in vivo
activation of gd T cells based on zoledronate plus low-
dose IL-2 application is ready to be explored in larger
clinical trials and in other tumor entities with poor
prognosis, for example, pancreatic ductal adenocarci-
noma where it might be combined with standard
regimens such as gemcitabine. It is conceivable that
this protocol can be further improved, for instance, by
combination with tumor-targeting monoclonal antibo-
dies. Along this line, it has been shown that B-cell
lymphoma or breast tumor cell killing by Fcg receptor-
expressing gd T cells is enhanced in the presence of
targeting antibodies rituximab (CD20) or trastuzumab
(HER2/neu), respectively [22]. Moreover, a gd T-cell-
stimulating synthetic phosphoantigen was found to
enhance the depletion of CD20
+ B cells by rituximab
in a non-human primate model in vivo, pointing to the
possible use of phosphoantigen plus anti-CD20 anti-
bodies in the treatment of CD20
+ leukemias and
lymphomas [23]. Furthermore, cytokines promoting
homeostatic proliferation and survival of T cells, such
as IL-15 [24], or cytokines potentiating the cytolytic
activity and pro-inflammatory response, such as IL-21
[25], might be combined with IL-2 or used instead of
IL-2. This could be considered both for in vivo application
together with N-BPs and for optimization of in vitro
expansion of gd T cells. In addition, future study
protocols might include the combination of in vivo
activation of gd T cells (by N-BP or phosphoantigen plus
IL-2) followed by the adoptive transfer of in vitro
expanded gd T cells, Finally, it should be stressed that
gd T-cell-based immunotherapy is not expected to
replace established therapeutic protocols. Rather, it
might offer additional benefit to the patient, for instance,
in combination with conventional chemotherapy [26].
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